Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth B Gottlin

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Plos One|June 29, 2017
Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibodyMark T Winkler, Ryan T Bushey, Elizabeth B Gottlin, et al.
Cancer|June 30, 2011
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303)Andrew S Roberts, Michael J Campa, Elizabeth B Gottlin, et al.
Frontiers in Oncology|October 4, 2021
Genetic Variants of <i>CLPP</i> and <i>M1AP</i> Are Associated With Risk of Non-Small Cell Lung CancerXianghan Li, Yiran Zou, Teng Li, et al.
Cell Reports|May 11, 2016
A Therapeutic Antibody for Cancer, Derived from Single Human B CellsRyan T Bushey, M Anthony Moody, Nathan L Nicely, et al.
Nature Communications|January 3, 2025
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trialJeffrey M Clarke, George R Simon, Hirva Mamdani, et al.
Frontiers in Oncology|January 23, 2023
Upregulation of complement proteins in lung cancer cells mediates tumor progressionEmily K Kleczko, Joanna M Poczobutt, Andre C Navarro, et al.
Cancer Immunology Research|April 28, 2026
Tumor-derived complement C3 overexpression in STK11-mutant lung adenocarcinoma drives tumor growth and immune checkpoint inhibitor resistanceSora Suzuki, Bojidar Kandar, Catrina Ting, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Plos One|June 29, 2017
Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibodyMark T Winkler, Ryan T Bushey, Elizabeth B Gottlin, et al.
Cancer|June 30, 2011
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303)Andrew S Roberts, Michael J Campa, Elizabeth B Gottlin, et al.
Frontiers in Oncology|October 4, 2021
Genetic Variants of <i>CLPP</i> and <i>M1AP</i> Are Associated With Risk of Non-Small Cell Lung CancerXianghan Li, Yiran Zou, Teng Li, et al.
Cell Reports|May 11, 2016
A Therapeutic Antibody for Cancer, Derived from Single Human B CellsRyan T Bushey, M Anthony Moody, Nathan L Nicely, et al.
Nature Communications|January 3, 2025
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trialJeffrey M Clarke, George R Simon, Hirva Mamdani, et al.
Frontiers in Oncology|January 23, 2023
Upregulation of complement proteins in lung cancer cells mediates tumor progressionEmily K Kleczko, Joanna M Poczobutt, Andre C Navarro, et al.
Cancer Immunology Research|April 28, 2026
Tumor-derived complement C3 overexpression in STK11-mutant lung adenocarcinoma drives tumor growth and immune checkpoint inhibitor resistanceSora Suzuki, Bojidar Kandar, Catrina Ting, et al.
Pageof 3